US · Healthcare · Biotechnology
EPS came in at -8.75 against a street estimate of -0.84 — a miss of 941.7%.
Analysts rate BlossomHill Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $35.40.
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BLOSSOMHILL THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash Position: $95.4 million as of June 30, 2026; decreased from $13 | 2026-09-18 |
| Results announced · Q3 2026 BLOSSOMHILL THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $23.8 million, or $(8.75) per share (vs. $13.2 m | 2026-09-18 |
| Reg FD disclosure · Q3 2026 BLOSSOMHILL THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: BlossomHill Therapeutics, Inc. (Ticker: BLSM, Nasdaq) • Filing Date: Septemb | 2026-09-15 |
| Charter / bylaws change · Q3 2026 BLOSSOMHILL THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company completed initial public offering (IPO) on August 10, 2026 • 9,375,000 share | 2026-08-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BlossomHill Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.